Tumor immunization. Improved results after vaccine modified with recombinant interferon gamma.
The purpose of this study was to determine if a 3-day in vitro culture of the murine neuroblastoma C1300 with 500 U/mL of recombinant interferon gamma resulted in a protective crossreactivity to parent C1300. Twenty A/J mice received either a vaccine of 1 x 10(6) irradiated C1300 tumor cells intradermally or an equivalent inoculum of C1300 that had been incubated in recombinant interferon gamma (C1300*). One week later, all animals were rechallenged with 1 x 10(6) viable C1300. Animals immunized with C1300* had a significantly delayed early tumor incidence that translated into a survival advantage for the group. At the time of tumor rechallenge, a significantly increased level of nonspecific systemic immunity was conferred by the C1300* immunization. Thus, modification of tumor with recombinant interferon gamma before introduction as a vaccine may improve that vaccine's protective capability.
Sigal
R K
RK
Harrison Department of Surgical Research, University of Pennsylvania School of Medicine, Philadelphia.
Lieberman
M D
MD
Reynolds
J V
JV
Williams
N
N
Ziegler
M M
MM
Daly
J M
JM
D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D007114:Immunization / Q000379:methods*; D007371:Interferon-gamma / Q000276:immunology*; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D009368:Neoplasm Transplantation / Q000379:methods; D009447:Neuroblastoma / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D011994:Recombinant Proteins; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000276:immunology; D014612:Vaccines / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*
D001500:BCG Vaccine; D011994:Recombinant Proteins; D014612:Vaccines; D014614:Vaccines, Synthetic; D007371:Interferon-gamma